1 Deer Park Drive
7 articles with Elucida Oncology
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
Elucida Oncology announced today that Geno Germano, CEO and President of Elucida Oncology, and Ian Somaiya, CFO and CBO of Elucida Oncology, will present at two upcoming virtual investor conferences: The 40th Annual J.P. Morgan Healthcare Conference Date: Tuesday, January 11, 2022 Time: 8:30 a.m. EST.
Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, provided a corporate update and announced its strategic priorities and anticipated milestones.
Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering & Therapeutic Conference
Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Gregory Adams, Ph.D., Chief Scientific Officer, will be presenting on Thursday, December 16th at 8:30am PST at the Antibody Engineering & Therapeutics Conference.
The precision medicine company is developing mutant selective and isoform-specific drugs in non-conventional ways for well-known targets in the oncology and autoimmune spaces.
Elucida Oncology announced today the appointment of Ian Somaiya as Chief Financial Officer and Chief Business Officer.
Cancer companies Delfi Diagnostics and Elucida Oncology announced Series A raises worth $144 million so far.